Stock Research for INFI


Featured Broker: Ally Invest

Get the due diligence for another stock.


INFI Stock Chart & Research Data

The INFI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INFI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


INFI Due diligence Resources & Stock Charts

The INFI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View INFI Detailed Price Forecast - CNN Money CNN View INFI Detailed Summary - Google Finance
Yahoo View INFI Detailed Summary - Yahoo! Finance Zacks View INFI Stock Research & Analysis -

Stock Analysis

TradeIdeas View INFI Trends & Analysis - Trade-Ideas Barrons View INFI Major Holders - Barrons
NASDAQ View INFI Call Transcripts - NASDAQ Seeking View INFI Breaking News & Analysis - Seeking Alpha
Spotlight View INFI Annual Report - OTC Report View INFI OTC Short Report -
TradeKing View INFI Fundamentals - TradeKing Charts View INFI SEC Filings - Bar Chart
WSJ View Historical Prices for INFI - The WSJ Morningstar View Performance/Total Return for INFI - Morningstar
MarketWatch View the Analyst Estimates for INFI - MarketWatch CNBC View the Earnings History for INFI - CNBC
StockMarketWatch View the INFI Earnings - StockMarketWatch MacroAxis View INFI Buy or Sell Recommendations - MacroAxis
Bullish View the INFI Bullish Patterns - American Bulls Short Pains View INFI Short Pain Metrics -

Social Media Mentions

StockTwits View INFI Stock Mentions - StockTwits PennyStocks View INFI Stock Mentions - PennyStockTweets
Twitter View INFI Stock Mentions - Twitter Invest Hub View INFI Investment Forum News - Investor Hub
Yahoo View INFI Stock Mentions - Yahoo! Message Board Seeking Alpha View INFI Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for INFI - Insider Cow View Insider Transactions for INFI - Insider Cow
CNBC View INFI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for INFI - OTC Markets
Yahoo View Insider Transactions for INFI - Yahoo! Finance NASDAQ View Institutional Holdings for INFI - NASDAQ

Stock Charts

FinViz View INFI Stock Insight & Charts - StockCharts View INFI Investment Charts -
BarChart View INFI Stock Overview & Charts - BarChart Trading View View INFI User Generated Charts - Trading View

Latest Financial News for INFI

Edited Transcript of INFI earnings conference call or presentation 5-Nov-18 9:30pm GMT
Posted on Tuesday November 13, 2018

Q3 2018 Infinity Pharmaceuticals Inc Earnings Call

Today’s Research Reports on Stocks to Watch: Infinity Pharmaceuticals and athenahealth
Posted on Tuesday November 13, 2018

Inc. were in the green after announcing the company will be acquired for $5.7 billion in cash by Veritas Capital and Evergreen Coast Capital. Infinity Pharmaceuticals, Inc. shares closed down 45.42% on about 4.6 million shares traded yesterday. "Today's data validate our scientific rationale for the development of IPI-549 as a potentially first-in-class therapeutic alternative for patients lacking better treatment options," said Adelene Perkins, Chief Executive Officer of Infinity Pharmaceuticals.

Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO‑1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC's 33rd Annual Meeting
Posted on Saturday November 10, 2018

CAMBRIDGE, Mass., Nov. 10, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) announced that data to be presented today at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrated preliminary evidence that IPI-549 in combination with Opdivo® (nivolumab) is clinically active in indications not expected to respond to Opdivo alone. In particular, evidence of reversal of resistance to Opdivo included a partial response in a patient with metastatic melanoma who progressed on immediate prior Opdivo therapy.

Detailed Research: Economic Perspectives on MetLife, Callon Petroleum, Five9, Ballard Power, Infinity Pharmaceuticals, and Commercial Vehicle Group — What Drives Growth in Today's Competitive Landscape
Posted on Friday November 09, 2018

NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.